세프토비프롤
|
|
세프토비프롤 속성
- 밀도
- 2.00±0.1 g/cm3(Predicted)
- 저장 조건
- Store at -20°C,unstable in solution, ready to use.
- 용해도
- DMSO : 5 mg/mL (9.35 mM)
- 산도 계수 (pKa)
- 2.46±0.50(Predicted)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
| 그림문자(GHS): | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 신호 어: | Danger | ||||||||||||||||||||||||||||||||
| 유해·위험 문구: |
|
||||||||||||||||||||||||||||||||
| 예방조치문구: |
|
세프토비프롤 C화학적 특성, 용도, 생산
용도
Broad spectrum antibiotic.Antimicrobial activity
The most important property distinguishing it from older cephalosporins is activity against methicillin-resistant staphylococci, a property conferred by a high affinity for penicillinbinding protein 2′ (2a). MICs for methicillin-resistant strains are nevertheless somewhat higher than those seen with fully susceptible strains. A similar situation exists with coagulasenegative staphylococci and with Str. pneumoniae, for which strains with reduced susceptibility to penicillin are less susceptible than fully resistant strains, while remaining within therapeutically achievable levels.Otherwise activity approximates to that of cephalosporins of group 4 . Activity against Ps. aeruginosa is modest and much reduced against ceftazidime-resistant strains.
원료
It is hydrolyzed by extended spectrum β-lactamases of enterobacteria , which are therefore resistant. The prospects for the emergence of resistance during extensive clinical use are presently unclear, though increased resistance in Staph. aureus appears to be difficult to induce under laboratory conditions.Pharmacokinetics
Cmax 500 mg (667 mg prodrug): c. 35 mg/L end infusionintravenous (30-min infusion)
Plasma half-life: c. 3 h
Volume of distribution: 18.4 L
Plasma protein binding: 16%
The prodrug is rapidly hydrolyzed in plasma to release the active form together with diacetyl (2,3-butanediol) and CO2. Distribution approximates to the extracellular fluid volume in adults. There is no accumulation on repeat dosing in subjects with normal renal function.
It is chiefly excreted in urine by glomerular filtration. A urinary concentration exceeding 1 g/L is achieved within the first 2 h of a 500 mg (active drug equivalent) dose and 80–90% of active drug can be recovered within 24 h.
Clinical Use
Ceftobiprole can be used as Broad spectrum antibiotic and in complicated infections of skin and skin structures.부작용
Limited studies have so far revealed no unexpected side effects. Nausea, vomiting and altered taste sensation appear to be the most common.세프토비프롤 준비 용품 및 원자재
원자재
준비 용품
세프토비프롤 공급 업체
글로벌( 59)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| career henan chemical co | +86-0371-86658258 |
sales@coreychem.com | China | 29914 | 58 |
| BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19553 | 58 |
| Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 |
sales@chemdad.com | China | 39916 | 58 |
| Alchem Pharmtech,Inc. | 8485655694 |
sales@alchempharmtech.com | United States | 63711 | 58 |
| Hebei Guanlang Biotechnology Co,.LTD | +86-19930503253; +8619930503252 |
daisy@crovellbio.com | China | 5956 | 58 |
| CR Corporation Lomited | |
fred.wen@crcorporation.cn | CHINA | 12069 | 58 |
| Alfa Chemistry | +1-5166625404 |
Info@alfa-chemistry.com | United States | 21317 | 58 |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 |
masar@topule.com | China | 8474 | 58 |
| LEAPCHEM CO., LTD. | +86-852-30606658 |
market18@leapchem.com | China | 43348 | 58 |
| Shanghai Acmec Biochemical Technology Co., Ltd. | +undefined18621343501 |
product@acmec-e.com | China | 33350 | 58 |